Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation
Top Cited Papers
Open Access
- 27 November 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 116 (22) , 2563-2570
- https://doi.org/10.1161/circulationaha.107.737312
Abstract
Background— Pharmacogenetic-guided dosing of warfarin is a promising application of “personalized medicine” but has not been adequately tested in randomized trials.Keywords
This publication has 37 references indexed in Scilit:
- Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisalThrombosis Research, 2006
- Genomic Medicine — A PrimerNew England Journal of Medicine, 2002
- Pharmacogenetics and drug-induced arrhythmiasCardiovascular Research, 2001
- Pharmacogenomics: Unlocking the Human Genome for Better Drug TherapyAnnual Review of Pharmacology and Toxicology, 2001
- A physical map of the human genomeNature, 2001
- Drug Target PharmacogenomicsAmerican Journal of PharmacoGenomics, 2001
- CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substratesPharmacogenetics, 2000
- Pharmacogenomics: Translating Functional Genomics into Rational TherapeuticsScience, 1999
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductasePharmacogenetics, 1997